Measured
Your result
No broken links found in this sample.
- Link health
- 100.00/100
- Quality checklist
- 85.54/100
- Broken links
- 0
Healthy links in the sample
Scored technical checks
Confirmed in sample
90 links verified · 110 unknown · 20 selected source pages · 45% of selected destinations verified. Sample only. Unknown links are not counted as broken.
What to fix first
View all priorities →Includes issues from the extended diagnostic report.
- Fix 1 diagnostic broken link
Start with navigation and internal links so visitors can reach your pages.
- Image dimensions declared
Declare width and height attributes (or an inline aspect-ratio style) on every visible <img> so the browser reserves space before the image loads. Reference: web.dev / Lighthouse "image elements have explicit width and height" (layout shift).
- Structured data syntax
Provide JSON-LD with @context and @type (or a typed @graph). Match the markup to the visible content; syntax alone does not validate its meaning. Reference: schema.org and Google structured data guidelines.
Fix with your coding assistant
Copy a ready-to-use prompt with the issues and affected URLs.
Your path to S-Tier
Not yet S-TierHealthy links, every scored requirement passed, and complete evidence in the selected sample.
- Pass all scored quality requirements across the five categories.
- Verify every required check and selected destination; incomplete or retained evidence cannot unlock the badge.
How this result qualifies
Verified internal navigation
At least 10 internal destinations were verified. Unknown items do not disqualify the site; confirmed checklist failures reduce quality.
100.00/100 link health · 85.54/100 quality · 90 internal destinations
New comparison baseline. A change in coverage is not a verified improvement.
The diagnostic report below may cover additional pages and external links. Only the stored competitive sample determines the ranking. At least 10 verified internal links are required; unavailable checklist items do not exclude a site. How scoring works
Explore issues & evidenceIssues & evidenceConfirmed issues, suggested fixes and the evidence behind them.
Broken links & sources
Latest competitive sample and evidence · 85.54/100 quality
At least 10 internal destinations were verified. Unknown items do not disqualify the site; confirmed checklist failures reduce quality. The available outcomes agreed between passes.
20 selected source URLs · 200 internal destinations. 90 evaluated · 110 unknown · 0 using previous evidence. The expanded diagnostic report follows below.
Some checklist evidence is unavailable: Homepage sharing image available, Root sitemap available. 0 check(s) use previous evidence, for at most eight days from their last reliable reading. Other unknown observations have no scoring vote.
- SEO
- 100.00/100
- Accessibility
- 98.00/100
- Structure
- 49.17/100
- Sharing
- 87.50/100
- Security
- 100.00/100
Selected pages
- https://www.roche.com/
- https://www.roche.com/about
- https://www.roche.com/about/business
- https://www.roche.com/about/business/diagnostics
- https://www.roche.com/about/business/pharmaceuticals
- https://www.roche.com/about/governance
- https://www.roche.com/about/governance/annual-general-meetings
- https://www.roche.com/about/governance/board-of-directors
- https://www.roche.com/about/governance/code-of-conduct
- https://www.roche.com/about/governance/committees
- https://www.roche.com/about/governance/executive-committee
- https://www.roche.com/about/governance/risk-management
- https://www.roche.com/about/history
- https://www.roche.com/about/leadership
- https://www.roche.com/about/roche-global-citizenship
- https://www.roche.com/about/strategy
- https://www.roche.com/about/sustainability
- https://www.roche.com/about/sustainability/approach
- https://www.roche.com/about/sustainability/esg-index
- https://www.roche.com/about/sustainability/goals-performance
Internal link verdicts and weights
- ok · weight 6 · https://careers.roche.com/
- ok · weight 6 · https://diagnostics.roche.com/
- ok · weight 6 · https://forpatients.roche.com/
- ok · weight 6 · https://medinfo.roche.com/
- ok · weight 6 · https://suppliers.roche.com/
- ok · weight 6 · https://www.roche.com/
- ok · weight 6 · https://www.roche.com/about
- ok · weight 6 · https://www.roche.com/about/business
- ok · weight 6 · https://www.roche.com/about/business/diagnostics
- ok · weight 6 · https://www.roche.com/about/business/pharmaceuticals
- ok · weight 6 · https://www.roche.com/about/governance
- ok · weight 6 · https://www.roche.com/about/governance/annual-general-meetings
- ok · weight 6 · https://www.roche.com/about/governance/board-of-directors
- ok · weight 6 · https://www.roche.com/about/governance/code-of-conduct
- ok · weight 6 · https://www.roche.com/about/governance/committees
- ok · weight 6 · https://www.roche.com/about/governance/executive-committee
- ok · weight 6 · https://www.roche.com/about/governance/risk-management
- ok · weight 6 · https://www.roche.com/about/history
- ok · weight 6 · https://www.roche.com/about/leadership
- ok · weight 6 · https://www.roche.com/about/roche-global-citizenship
- ok · weight 6 · https://www.roche.com/about/strategy
- ok · weight 6 · https://www.roche.com/about/sustainability
- ok · weight 6 · https://www.roche.com/about/sustainability/approach
- ok · weight 6 · https://www.roche.com/about/sustainability/esg-index
- ok · weight 6 · https://www.roche.com/about/sustainability/goals-performance
- ok · weight 6 · https://www.roche.com/accessibility-statement
- ok · weight 6 · https://www.roche.com/contact
- ok · weight 6 · https://www.roche.com/innovation
- ok · weight 6 · https://www.roche.com/innovation/clinical-trials
- ok · weight 6 · https://www.roche.com/innovation/ethical-standards
- ok · weight 6 · https://www.roche.com/innovation/ethical-standards/advisory
- ok · weight 6 · https://www.roche.com/innovation/ethical-standards/animal-research
- ok · weight 6 · https://www.roche.com/innovation/ethical-standards/genetics
- ok · weight 6 · https://www.roche.com/innovation/partnering
- ok · weight 6 · https://www.roche.com/innovation/partnering/areas-of-interest
- ok · weight 6 · https://www.roche.com/innovation/partnering/diagnostics
- ok · weight 6 · https://www.roche.com/innovation/partnering/pharma
- ok · weight 6 · https://www.roche.com/innovation/process
- ok · weight 6 · https://www.roche.com/innovation/structure
- ok · weight 6 · https://www.roche.com/innovation/structure/rnd-locations
- ok · weight 6 · https://www.roche.com/investors
- ok · weight 6 · https://www.roche.com/investors/annualreport25
- ok · weight 6 · https://www.roche.com/investors/bonds
- ok · weight 6 · https://www.roche.com/investors/downloads
- ok · weight 6 · https://www.roche.com/investors/events
- ok · weight 6 · https://www.roche.com/investors/faq_investors
- ok · weight 6 · https://www.roche.com/investors/reports
- ok · weight 6 · https://www.roche.com/investors/rofis
- ok · weight 6 · https://www.roche.com/investors/updates
- ok · weight 6 · https://www.roche.com/legal-statement
- ok · weight 6 · https://www.roche.com/locations
- ok · weight 6 · https://www.roche.com/media
- ok · weight 6 · https://www.roche.com/media/events
- ok · weight 6 · https://www.roche.com/media/library-images
- ok · weight 6 · https://www.roche.com/media/releases
- ok · weight 6 · https://www.roche.com/media/statements
- ok · weight 6 · https://www.roche.com/our-websites
- ok · weight 6 · https://www.roche.com/privacy-notice
- ok · weight 6 · https://www.roche.com/search
- ok · weight 6 · https://www.roche.com/solutions
- ok · weight 6 · https://www.roche.com/solutions/diagnostics
- ok · weight 6 · https://www.roche.com/solutions/diagnostics/safety-officers
- ok · weight 6 · https://www.roche.com/solutions/focus-areas
- ok · weight 6 · https://www.roche.com/solutions/focus-areas/cardiometabolic
- ok · weight 6 · https://www.roche.com/solutions/focus-areas/diabetes
- ok · weight 6 · https://www.roche.com/solutions/focus-areas/haematology
- ok · weight 6 · https://www.roche.com/solutions/focus-areas/immunology
- ok · weight 6 · https://www.roche.com/solutions/focus-areas/infectious-diseases
- ok · weight 6 · https://www.roche.com/solutions/focus-areas/inflammatory-bowel-diseases
- ok · weight 6 · https://www.roche.com/solutions/focus-areas/neurology
- ok · weight 6 · https://www.roche.com/solutions/focus-areas/oncology
- ok · weight 6 · https://www.roche.com/solutions/focus-areas/ophthalmology
- ok · weight 6 · https://www.roche.com/solutions/focus-areas/respiratory
- ok · weight 6 · https://www.roche.com/solutions/focus-areas/womens-health
- ok · weight 6 · https://www.roche.com/solutions/pharma
- ok · weight 6 · https://www.roche.com/solutions/pharma/safety-reporting
- ok · weight 6 · https://www.roche.com/solutions/pipeline
- ok · weight 6 · https://www.roche.com/some-guidelines
- ok · weight 6 · https://www.roche.com/stories
- ok · weight 4 · https://careers.roche.com/global/en
- ok · weight 4 · https://www.roche.com/about/
- ok · weight 4 · https://www.roche.com/about/inclusion-belonging
- ok · weight 4 · https://www.roche.com/innovation/
- ok · weight 4 · https://www.roche.com/investors/
- ok · weight 4 · https://www.roche.com/investors/updates/inv-update-2026-10-22
- ok · weight 4 · https://www.roche.com/media/
- ok · weight 4 · https://www.roche.com/solutions/
- ok · weight 4 · https://www.roche.com/stories/genomic-oncology-sbx-sequencing
- ok · weight 4 · https://www.roche.com/stories/multiple-sclerosis-relapsing-progressive-biology
- ok · weight 4 · https://www.roche.com/stories/whats-it-worth/
- unverifiable · weight 2 · https://assets.cwp.roche.com/f/126832/c8490a6058/agm19_sas_e.pdf
- unverifiable · weight 2 · https://assets.cwp.roche.com/f/176343/x/4cbedb1b44/englisch_einladung_roche_2024.pdf
- unverifiable · weight 2 · https://assets.cwp.roche.com/f/176343/x/b5b1101e29/deutsch_einladung_roche_2024.pdf
- unverifiable · weight 2 · https://assets.cwp.roche.com/f/176343/x/e340f7a146/franzoesisch_einladung_roche_2024.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/0393a4adb1/agm18_minutes.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/053f7333f3/einladung_gv_2020_d.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/093feb6d90/code_of_conduct_tr.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/0efecf9088/code_of_conduct_it.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/0f3b554383/code_of_conduct_de.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/11819d0ba1/roche_dividend_2017_e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/12cbc89b26/agm19_results_d.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/135a9723b0/einladung_gv_2018_f.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/14b0e2573c/roche_dividende_2021_d.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/22ec5af3af/agm18_sas_e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/26ab377498/code_of_conduct_pt-br.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/2bd5d32efe/roche_dividend_2017_f.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/317f796417/agm18_results_d.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/31db830030/roche_dividend_2018_d.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/422b3961b3/code_of_conduct_jp.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/422ed2bde8/agm17_cf_e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/4a4fb036ca/25_position_she_in_the_supply_chain_reviewed_april_2020.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/4c14bfb374/agm19_protokoll.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/4dc358f568/einladung_gv_2018_d.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/547b44f593/roche_dividende_2021_f.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/56e3990739/einladung_gv_2018_e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/5a10a2efd5/einladung_gv_2020_f.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/5f6096f724/position-on-trips.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/6683a5d6a1/agm20_dividend_2019_e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/68fd0c759c/agm20_dividend_2019_f.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/69245201af/agm18_protokoll.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/6e13a4072b/einladung_gv_2021_e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/7676961955/3-global_statement_on_biodiversity_2020.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/7f9e128998/agm18_cf_e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/801584573d/roche-position-ip.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/806c363ca6/einladung_gv_2021_d.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/85179c3772/agm17_sas_e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/861fa09dd8/23_roche_position_product_stewardship_reviewed_april_2020.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/8a1eda9599/code_of_conduct_ru.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/9524e20996/roche_dividende_2021_e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/96ee385a34/21_position_preventing_reducing_pollution_reviewed_april_2020.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/97b5253909/agm19_dividend_2018_e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/9aa73f4eb8/einladung_gv_2017_f.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/a29f6b1350/einladung_gv_2017_e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/a6315ef1f4/22_position_waste_management_roche_reviewed_april_2020.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/b1cedac68d/code_of_conduct_fr.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/b6ce28599a/protokoll_103_gv_roche_holding_ag_2021_e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/b6f566a27b/roche_dividend_2018_f.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/b91cbe07de/gv21_rede_cf_e_final.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/bb0f929065/roche_dividend_2018_e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/bd828ec4a9/agm17_minutes.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/c0dba009df/protokoll_103_gv_roche_holding_ag_2021_d.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/c32e118c72/roche_dividend_2017_d.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/c5066cdcfa/code_of_conduct_cn.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/ca74efc06b/agm20_minutes.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/cc99b26c8b/agm19_dividend_2018_d.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/d03d051d10/einladung_gv_2020_e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/d0881eab94/roche_statuten_2019_d_tracked.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/d0a15caa74/roche_statuten_2019_e_tracked.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/d491976a14/agm19_cf_e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/d49a8f3468/einladung_gv_2017_d.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/d7257173a7/agm20_dividend_2019_d.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/d8793d05ff/einladung_gv_2019_d.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/d9c9e7e13d/agm20_results_d-pdf.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/db1d9398d2/einladung_gv_2019_e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/dbdb72d1f6/agm17_protokoll.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/e0b54776a7/code-of-conduct.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/e3b20b0e63/agm20_protokoll.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/e9f74a0455/210316_resultate_final_testaris_ag.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/eb923f019a/einladung_gv_2019_f.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/f6352123a5/code_of_conduct_es.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/f7cbd5347d/agm19_minutes.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/f83232cee2/agm17_results_d.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/0079594d88/gv-2024_ts_e_speech.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/01049dc2e8/gv-2023_rede_ts_e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/02547253fa/energy-consumption-fact-sheet.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/039986a931/ar25e-rem.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/0742642df0/26-position-respecting-human-rights-reviewed-april-2020.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/08e107cbfb/def-d-einladung-ao-gv-roche-2021-format-200x380-mm.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/09457b2a19/ar24e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/11066db41a/roche_statuten_2023_en.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/124e641cb6/scope-1-and-2-greenhouse-gas-emissions.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/143938dd27/fb23d.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/15e6430e4d/agm25_speech-ts_en.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/1cc4e31e9e/other-emissions-to-air-fact-sheet.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/1eb0ebd1dd/ar21e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/23f905471d/working-with-government-officials.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/251fcb024b/dr_christoph_franz_roche_gv.mp4
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/26d83932cc/def3_f_einladung_ao_gv_roche_2021_format-200x380-mm.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/29fd88c622/franzoesisch_einladung_agm_roche.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/2c0563b871/roche-approach-to-tax.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/2c31261e28/she-goals-2029.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/2c8b43d3aa/protokoll-108-gv-roche-holding-ag-2026-en_final_protected_version.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/31a707657c/biodiversity-fact-sheet.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/3431d7404a/use-of-water-fact-sheet.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/36158b783f/position_access_use_real_world_data.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/38ce107fe4/employment_policy.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/38d96ed8ec/fb24e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/39987fbe1d/agm16_minutes.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/39ddbb2577/def4-e-einladung-ao-gv-roche-2021-format-200x380-mm.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/3b1fb647e2/fb23e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/413ea95746/policy_on_donations_and_non-commercial_sponsorship.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/43f14540f2/ar22e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/44acd0293b/roche_gv_2022-einladungsinserat_d.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/4705a117cb/dividendeninserat_2023_f.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/48f34117f6/protokoll-106-gv-roche-holding-ag-2024-de.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/491677040d/roche-dividende-2024_f.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/49e981f7d1/protokoll-105-gv-roche-holding-ag-2023-e.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/4b728dadb5/fb25d.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/4d7995c964/she_policy.pdf
- unverifiable · weight 2 · https://assets.roche.com/f/176343/x/503fcf9b19/gv-2024_sas_e_speech.pdf
Scoring checks
- Page title: passed · 20/20 applicable observations
https://www.roche.com/: Roche - Doing now what patients need next
https://www.roche.com/about: Roche | About Roche
https://www.roche.com/about/business: Roche | Our business
https://www.roche.com/about/business/diagnostics: Roche | Roche Diagnostics
https://www.roche.com/about/business/pharmaceuticals: Roche | Roche Pharmaceuticals
- Distinct page titles: passed · 20/20 applicable observations
https://www.roche.com/: Roche - Doing now what patients need next
https://www.roche.com/about: Roche | About Roche
https://www.roche.com/about/business: Roche | Our business
https://www.roche.com/about/business/diagnostics: Roche | Roche Diagnostics
https://www.roche.com/about/business/pharmaceuticals: Roche | Roche Pharmaceuticals
- Meta description: passed · 20/20 applicable observations
https://www.roche.com/: As a pioneer in healthcare, we have been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.
https://www.roche.com/about: We unite leading science and technology across diagnostics, medicines, and digital solutions to prevent, stop and cure diseases.
https://www.roche.com/about/business: Our unique setup is the foundation of our success. The combined strength of our Diagnostics and Pharmaceuticals divisions enables us to positively impact patients, families, communities and healthcare systems around the world. We are committed to preventing, h
https://www.roche.com/about/business/diagnostics: We combine science, data and insights to transform the way diseases can be prevented, diagnosed and monitored. Our medical assays, digital solutions and services help people live healthier lives.
https://www.roche.com/about/business/pharmaceuticals: Developing innovative treatments across major disease areas, Roche Pharma is focused on translating excellence in science into effective medicines for patients.
- Self-referencing canonical: passed · 20/20 applicable observations
https://www.roche.com/: https://www.roche.com/
https://www.roche.com/about: https://www.roche.com/about
https://www.roche.com/about/business: https://www.roche.com/about/business
https://www.roche.com/about/business/diagnostics: https://www.roche.com/about/business/diagnostics
https://www.roche.com/about/business/pharmaceuticals: https://www.roche.com/about/business/pharmaceuticals
- Main heading: failed · 19/20 applicable observations
https://www.roche.com/: 0 H1 element(s)
https://www.roche.com/about: 1 H1 element(s)
https://www.roche.com/about/business: 1 H1 element(s)
https://www.roche.com/about/business/diagnostics: 1 H1 element(s)
https://www.roche.com/about/business/pharmaceuticals: 1 H1 element(s)
- Heading hierarchy: failed · 0/20 applicable observations
https://www.roche.com/: 1 skipped heading level(s)
https://www.roche.com/about: 2 skipped heading level(s)
https://www.roche.com/about/business: 1 skipped heading level(s)
https://www.roche.com/about/business/diagnostics: 2 skipped heading level(s)
https://www.roche.com/about/business/pharmaceuticals: 1 skipped heading level(s)
- Main landmark: passed · 20/20 applicable observations
https://www.roche.com/: 1 main landmarks
https://www.roche.com/about: 1 main landmarks
https://www.roche.com/about/business: 1 main landmarks
https://www.roche.com/about/business/diagnostics: 1 main landmarks
https://www.roche.com/about/business/pharmaceuticals: 1 main landmarks
- Mobile viewport: passed · 20/20 applicable observations
https://www.roche.com/: width=device-width, initial-scale=1.0
https://www.roche.com/about: width=device-width, initial-scale=1.0
https://www.roche.com/about/business: width=device-width, initial-scale=1.0
https://www.roche.com/about/business/diagnostics: width=device-width, initial-scale=1.0
https://www.roche.com/about/business/pharmaceuticals: width=device-width, initial-scale=1.0
- Image dimensions declared: failed · 0/16 applicable observations
https://www.roche.com/: 14 of 14 images lack width/height attributes or an aspect-ratio style
https://www.roche.com/about: 8 of 8 images lack width/height attributes or an aspect-ratio style
https://www.roche.com/about/business: 3 of 3 images lack width/height attributes or an aspect-ratio style
https://www.roche.com/about/business/diagnostics: 11 of 11 images lack width/height attributes or an aspect-ratio style
https://www.roche.com/about/business/pharmaceuticals: 13 of 13 images lack width/height attributes or an aspect-ratio style
- Structured data syntax: failed · 0/20 applicable observations
https://www.roche.com/: 0 of 1 blocks have valid JSON-LD structure
https://www.roche.com/about: 0 of 0 blocks have valid JSON-LD structure
https://www.roche.com/about/business: 0 of 0 blocks have valid JSON-LD structure
https://www.roche.com/about/business/diagnostics: 0 of 0 blocks have valid JSON-LD structure
https://www.roche.com/about/business/pharmaceuticals: 0 of 0 blocks have valid JSON-LD structure
- Document language: passed · 20/20 applicable observations
https://www.roche.com/: en
https://www.roche.com/about: en
https://www.roche.com/about/business: en
https://www.roche.com/about/business/diagnostics: en
https://www.roche.com/about/business/pharmaceuticals: en
- Image alternatives declared: passed · 16/16 applicable observations
https://www.roche.com/about/governance/committees: 0 of 0 images lack an alt attribute
https://www.roche.com/about/governance/risk-management: 0 of 0 images lack an alt attribute
https://www.roche.com/about/sustainability/esg-index: 0 of 0 images lack an alt attribute
https://www.roche.com/about/sustainability/goals-performance: 0 of 0 images lack an alt attribute
https://www.roche.com/: 0 of 14 images lack an alt attribute
- Buttons named: passed · 20/20 applicable observations
https://www.roche.com/: 0 of 36 buttons have no HTML name
https://www.roche.com/about: 0 of 37 buttons have no HTML name
https://www.roche.com/about/business: 0 of 34 buttons have no HTML name
https://www.roche.com/about/business/diagnostics: 0 of 34 buttons have no HTML name
https://www.roche.com/about/business/pharmaceuticals: 0 of 38 buttons have no HTML name
- Links named: failed · 19/20 applicable observations
https://www.roche.com/about/governance/annual-general-meetings: 1 of 305 links have no HTML name
https://www.roche.com/: 0 of 138 links have no HTML name
https://www.roche.com/about: 0 of 129 links have no HTML name
https://www.roche.com/about/business: 0 of 123 links have no HTML name
https://www.roche.com/about/business/diagnostics: 0 of 133 links have no HTML name
- Descriptive link text: failed · 19/20 applicable observations
https://www.roche.com/about/sustainability: 3 of 124 links use generic text: "read more"
https://www.roche.com/: 0 of 138 links use generic text
https://www.roche.com/about: 0 of 129 links use generic text
https://www.roche.com/about/business: 0 of 123 links use generic text
https://www.roche.com/about/business/diagnostics: 0 of 133 links use generic text
- Open Graph title: passed · 20/20 applicable observations
https://www.roche.com/: Roche - Doing now what patients need next
https://www.roche.com/about: Roche | About Roche
https://www.roche.com/about/business: Roche | Our business
https://www.roche.com/about/business/diagnostics: Roche | Roche Diagnostics
https://www.roche.com/about/business/pharmaceuticals: Roche | Roche Pharmaceuticals
- Open Graph description: passed · 20/20 applicable observations
https://www.roche.com/: As a pioneer in healthcare, we have been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.
https://www.roche.com/about: We unite leading science and technology across diagnostics, medicines, and digital solutions to prevent, stop and cure diseases.
https://www.roche.com/about/business: Our unique setup is the foundation of our success. The combined strength of our Diagnostics and Pharmaceuticals divisions enables us to positively impact patients, families, communities and healthcare systems around the world. We are committed to preventing, h
https://www.roche.com/about/business/diagnostics: We combine science, data and insights to transform the way diseases can be prevented, diagnosed and monitored. Our medical assays, digital solutions and services help people live healthier lives.
https://www.roche.com/about/business/pharmaceuticals: Developing innovative treatments across major disease areas, Roche Pharma is focused on translating excellence in science into effective medicines for patients.
- Open Graph type: passed · 20/20 applicable observations
https://www.roche.com/: website
https://www.roche.com/about: website
https://www.roche.com/about/business: website
https://www.roche.com/about/business/diagnostics: website
https://www.roche.com/about/business/pharmaceuticals: website
- Open Graph URL: passed · 20/20 applicable observations
https://www.roche.com/: https://www.roche.com/home
https://www.roche.com/about: https://www.roche.com/about
https://www.roche.com/about/business: https://www.roche.com/about/business
https://www.roche.com/about/business/diagnostics: https://www.roche.com/about/business/diagnostics
https://www.roche.com/about/business/pharmaceuticals: https://www.roche.com/about/business/pharmaceuticals
- Open Graph image URL: passed · 20/20 applicable observations
https://www.roche.com/: https://assets.roche.com/f/176343/1920x1080/0234c60f2d/home-teaser.jpg
https://www.roche.com/about: https://assets.roche.com/f/176343/4000x2668/5a5b318674/06-pred-antibiotics-s2498-1.jpeg
https://www.roche.com/about/business: https://assets.roche.com/f/176343/1280x853/eb20db01aa/roche_3776.png
https://www.roche.com/about/business/diagnostics: https://assets.roche.com/f/176343/608x355/3137bcd1be/diagnostics-teaser.jpg
https://www.roche.com/about/business/pharmaceuticals: https://assets.roche.com/f/176343/608x355/f2d57ffe90/pharmaceuticals-teaser.jpg
- Open Graph image description: failed · 0/20 applicable observations
https://www.roche.com/: No sharing image description
https://www.roche.com/about: No sharing image description
https://www.roche.com/about/business: No sharing image description
https://www.roche.com/about/business/diagnostics: No sharing image description
https://www.roche.com/about/business/pharmaceuticals: No sharing image description
- Social card type: passed · 20/20 applicable observations
https://www.roche.com/: summary
https://www.roche.com/about: summary
https://www.roche.com/about/business: summary
https://www.roche.com/about/business/diagnostics: summary
https://www.roche.com/about/business/pharmaceuticals: summary
- HTTPS page: passed · 20/20 applicable observations
https://www.roche.com/: https://www.roche.com/
https://www.roche.com/about: https://www.roche.com/about
https://www.roche.com/about/business: https://www.roche.com/about/business
https://www.roche.com/about/business/diagnostics: https://www.roche.com/about/business/diagnostics
https://www.roche.com/about/business/pharmaceuticals: https://www.roche.com/about/business/pharmaceuticals
- No insecure embedded resources: passed · 20/20 applicable observations
https://www.roche.com/: 0 HTTP embedded resource URL(s)
https://www.roche.com/about: 0 HTTP embedded resource URL(s)
https://www.roche.com/about/business: 0 HTTP embedded resource URL(s)
https://www.roche.com/about/business/diagnostics: 0 HTTP embedded resource URL(s)
https://www.roche.com/about/business/pharmaceuticals: 0 HTTP embedded resource URL(s)
- Homepage favicon available: passed · 1/1 applicable observations
https://www.roche.com/favicon-32x32.png?v=7f5356ff0eaba89671bed4a1828ef379: HTTP 200; image/png
- Homepage sharing image available: unverified · 0/1 applicable observations
https://assets.roche.com/f/176343/1920x1080/0234c60f2d/home-teaser.jpg: The image could not be fetched within the network policy and 2 MB limit.
- Root sitemap available: unverified · 0/1 applicable observations
https://www.roche.com/sitemap.xml: HTTP 500; no sitemap root found
- Rendered color contrast: unverified · 0/1 applicable observations
https://www.roche.com/: Requires a browser or human assessment; excluded from points.
- Keyboard and focus behavior: unverified · 0/1 applicable observations
https://www.roche.com/: Requires a browser or human assessment; excluded from points.
- HSTS declared: passed · 1/1 applicable observations
https://www.roche.com/: Strict-Transport-Security: max-age=31536000
- Content Security Policy declared: passed · 1/1 applicable observations
https://www.roche.com/: Content-Security-Policy: frame-ancestors 'self' https://app.storyblok.com
Sample reference: 4a90ed247e6113e80c9d71c78521ed5473ec1f6ffebc30378799e566b1481155
- 404internal · Inner pageon 3 pageshttps://www.roche.com/about/sustainability/approach/risk-management
Highlight works in Chrome and Safari; the browser jumps to the first match.
Diagnostic checklist
21 passed · 10 need work · 5 not verified. Open a check for the evidence and suggested fix.
- SEO
- 77.21
- Accessibility
- 81.40
- Structure
- 51.94
- Sharing
- 77.78
- Security
- 100.00
- AI access
- 100.00
- Performance
- 93.02
HTTP response measurement
548 ms median to homepage response headers. Measurements: 548, 475, 2180 ms.
Same crawler, three sequential requests, DNS and TLS included. Timing is diagnostic only and never decides a position. This is server/network response, not browser loading or Core Web Vitals.
Your checklist over time
Sep 12
83.43/100
Oct 22
85.54/100
Same checklist version; page samples may differ. A score change does not by itself prove a particular issue was fixed.
Static checks inspect crawler-visible HTML; they do not certify accessibility or code quality.
SEO1 to improve
Page titlePassed
43/43 applicable observations passed. 1.00/1 checklist weight earned.
How to improve: Give each page a descriptive, non-empty <title>.
- https://www.roche.com/Roche - Doing now what patients need next
- https://www.roche.com/aboutRoche | About Roche
- https://www.roche.com/about/businessRoche | Our business
- https://www.roche.com/about/business/diagnosticsRoche | Roche Diagnostics
- https://www.roche.com/about/business/pharmaceuticalsRoche | Roche Pharmaceuticals
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Distinct page titlesNeeds work
37/43 applicable observations passed. 0.86/1 checklist weight earned.
How to improve: Use a title that describes the purpose of this page rather than repeating the same title across URLs.
- https://www.roche.com/aboutRoche | About Roche
- https://www.roche.com/about/Roche | About Roche
- https://www.roche.com/innovationRoche | Innovation
- https://www.roche.com/innovation/Roche | Innovation
- https://www.roche.com/investorsRoche | Investors
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Meta descriptionPassed
43/43 applicable observations passed. 1.00/1 checklist weight earned.
How to improve: Add a non-empty meta name="description" that summarizes this page.
- https://www.roche.com/As a pioneer in healthcare, we have been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.
- https://www.roche.com/aboutWe unite leading science and technology across diagnostics, medicines, and digital solutions to prevent, stop and cure diseases.
- https://www.roche.com/about/businessOur unique setup is the foundation of our success. The combined strength of our Diagnostics and Pharmaceuticals divisions enables us to positively impact patients, families, communities and healthcare systems around the world. We are committed to preventing, h
- https://www.roche.com/about/business/diagnosticsWe combine science, data and insights to transform the way diseases can be prevented, diagnosed and monitored. Our medical assays, digital solutions and services help people live healthier lives.
- https://www.roche.com/about/business/pharmaceuticalsDeveloping innovative treatments across major disease areas, Roche Pharma is focused on translating excellence in science into effective medicines for patients.
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Self-referencing canonicalPassed
43/43 applicable observations passed. 1.00/1 checklist weight earned.
How to improve: Declare exactly one <link rel="canonical"> whose absolute URL is this page's own final URL (same scheme, host, path and query; only a trailing slash or fragment may differ). Cross-URL canonicals belong on duplicate pages, not on the indexable page itself. Reference: Google Search Central, canonicalization.
- https://www.roche.com/https://www.roche.com/
- https://www.roche.com/abouthttps://www.roche.com/about
- https://www.roche.com/about/businesshttps://www.roche.com/about/business
- https://www.roche.com/about/business/diagnosticshttps://www.roche.com/about/business/diagnostics
- https://www.roche.com/about/business/pharmaceuticalshttps://www.roche.com/about/business/pharmaceuticals
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Root sitemap availableNot verified
0/1 applicable observations passed. 0.00/1 checklist weight earned.
How to improve: Publish a sitemap URL set or index at /sitemap.xml. This checks its root, not every listed URL.
- https://www.roche.com/sitemap.xmlHTTP 500; no sitemap root found
Accessibility3 to improve
Document languagePassed
43/43 applicable observations passed. 1.00/1 checklist weight earned.
How to improve: Declare a valid language tag on the html element, such as en or pt-BR.
- https://www.roche.com/en
- https://www.roche.com/abouten
- https://www.roche.com/about/businessen
- https://www.roche.com/about/business/diagnosticsen
- https://www.roche.com/about/business/pharmaceuticalsen
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Image alternatives declaredPassed
35/35 applicable observations passed. 1.00/1 checklist weight earned.
How to improve: Add alt text to informative images. Use alt="" for decorative images. This check does not judge text quality.
- https://www.roche.com/about/governance/committees0 of 0 images lack an alt attribute
- https://www.roche.com/about/governance/risk-management0 of 0 images lack an alt attribute
- https://www.roche.com/about/sustainability/esg-index0 of 0 images lack an alt attribute
- https://www.roche.com/about/sustainability/goals-performance0 of 0 images lack an alt attribute
- https://www.roche.com/accessibility-statement0 of 0 images lack an alt attribute
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Form controls namedNeeds work
0/1 applicable observations passed. 0.00/1 checklist weight earned.
How to improve: Associate a label with each visible form control, or provide a non-empty aria-label / valid aria-labelledby.
- https://www.roche.com/0 of 0 controls have no HTML label
- https://www.roche.com/about0 of 0 controls have no HTML label
- https://www.roche.com/about/business0 of 0 controls have no HTML label
- https://www.roche.com/about/business/diagnostics0 of 0 controls have no HTML label
- https://www.roche.com/about/business/pharmaceuticals0 of 0 controls have no HTML label
Links namedNeeds work
42/43 applicable observations passed. 0.98/1 checklist weight earned.
How to improve: Give every link visible text or a meaningful accessible name.
- https://www.roche.com/about/governance/annual-general-meetings1 of 305 links have no HTML name
- https://www.roche.com/0 of 138 links have no HTML name
- https://www.roche.com/about0 of 129 links have no HTML name
- https://www.roche.com/about/business0 of 123 links have no HTML name
- https://www.roche.com/about/business/diagnostics0 of 133 links have no HTML name
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Descriptive link textNeeds work
39/43 applicable observations passed. 0.91/1 checklist weight earned.
How to improve: Replace generic link text such as "click here", "read more" or "saiba mais" with text (or an aria-label) that describes the destination. Reference: WCAG 2.4.4 Link Purpose (In Context).
- https://www.roche.com/about/sustainability3 of 124 links use generic text: "read more"
- https://www.roche.com/contact1 of 136 links use generic text: "here"
- https://www.roche.com/innovation/clinical-trials2 of 126 links use generic text: "read more"
- https://www.roche.com/innovation/ethical-standards/animal-research1 of 120 links use generic text: "read more"
- https://www.roche.com/0 of 138 links use generic text
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Rendered color contrastNot verified
0/1 applicable observations passed. Informational; excluded from points.
How to improve: Check foreground/background contrast in the rendered page.
- https://www.roche.com/Requires a browser or human assessment; excluded from points.
Keyboard and focus behaviorNot verified
0/1 applicable observations passed. Informational; excluded from points.
How to improve: Test every interactive control with a keyboard and inspect focus visibility.
- https://www.roche.com/Requires a browser or human assessment; excluded from points.
Structure4 to improve
Main headingNeeds work
42/43 applicable observations passed. 0.98/1 checklist weight earned.
How to improve: Add a descriptive H1 identifying the main topic.
- https://www.roche.com/0 H1 element(s)
- https://www.roche.com/about1 H1 element(s)
- https://www.roche.com/about/business1 H1 element(s)
- https://www.roche.com/about/business/diagnostics1 H1 element(s)
- https://www.roche.com/about/business/pharmaceuticals1 H1 element(s)
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Heading hierarchyNeeds work
6/43 applicable observations passed. 0.14/1 checklist weight earned.
How to improve: Nest headings logically without skipping a level, starting with H1.
- https://www.roche.com/1 skipped heading level(s)
- https://www.roche.com/about2 skipped heading level(s)
- https://www.roche.com/about/business1 skipped heading level(s)
- https://www.roche.com/about/business/diagnostics2 skipped heading level(s)
- https://www.roche.com/about/business/pharmaceuticals1 skipped heading level(s)
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Main landmarkPassed
43/43 applicable observations passed. 1.00/1 checklist weight earned.
How to improve: Mark the main content with one <main> or role="main" landmark.
- https://www.roche.com/1 main landmarks
- https://www.roche.com/about1 main landmarks
- https://www.roche.com/about/business1 main landmarks
- https://www.roche.com/about/business/diagnostics1 main landmarks
- https://www.roche.com/about/business/pharmaceuticals1 main landmarks
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Mobile viewportPassed
43/43 applicable observations passed. 1.00/1 checklist weight earned.
How to improve: Add meta name="viewport" with width=device-width and do not disable user zoom.
- https://www.roche.com/width=device-width, initial-scale=1.0
- https://www.roche.com/aboutwidth=device-width, initial-scale=1.0
- https://www.roche.com/about/businesswidth=device-width, initial-scale=1.0
- https://www.roche.com/about/business/diagnosticswidth=device-width, initial-scale=1.0
- https://www.roche.com/about/business/pharmaceuticalswidth=device-width, initial-scale=1.0
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Image dimensions declaredNeeds work
0/35 applicable observations passed. 0.00/1 checklist weight earned.
How to improve: Declare width and height attributes (or an inline aspect-ratio style) on every visible <img> so the browser reserves space before the image loads. Reference: web.dev / Lighthouse "image elements have explicit width and height" (layout shift).
- https://www.roche.com/14 of 14 images lack width/height attributes or an aspect-ratio style
- https://www.roche.com/about8 of 8 images lack width/height attributes or an aspect-ratio style
- https://www.roche.com/about/business3 of 3 images lack width/height attributes or an aspect-ratio style
- https://www.roche.com/about/business/diagnostics11 of 11 images lack width/height attributes or an aspect-ratio style
- https://www.roche.com/about/business/pharmaceuticals13 of 13 images lack width/height attributes or an aspect-ratio style
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Structured data syntaxNeeds work
0/43 applicable observations passed. 0.00/1 checklist weight earned.
How to improve: Provide JSON-LD with @context and @type (or a typed @graph). Match the markup to the visible content; syntax alone does not validate its meaning. Reference: schema.org and Google structured data guidelines.
- https://www.roche.com/0 of 1 blocks have valid JSON-LD structure
- https://www.roche.com/about0 of 0 blocks have valid JSON-LD structure
- https://www.roche.com/about/business0 of 0 blocks have valid JSON-LD structure
- https://www.roche.com/about/business/diagnostics0 of 0 blocks have valid JSON-LD structure
- https://www.roche.com/about/business/pharmaceuticals0 of 0 blocks have valid JSON-LD structure
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Sharing1 to improve
Open Graph titlePassed
43/43 applicable observations passed. 1.00/1 checklist weight earned.
How to improve: Provide a non-empty og:title meta property.
- https://www.roche.com/Roche - Doing now what patients need next
- https://www.roche.com/aboutRoche | About Roche
- https://www.roche.com/about/businessRoche | Our business
- https://www.roche.com/about/business/diagnosticsRoche | Roche Diagnostics
- https://www.roche.com/about/business/pharmaceuticalsRoche | Roche Pharmaceuticals
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Open Graph descriptionPassed
43/43 applicable observations passed. 1.00/1 checklist weight earned.
How to improve: Provide a non-empty og:description meta property.
- https://www.roche.com/As a pioneer in healthcare, we have been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.
- https://www.roche.com/aboutWe unite leading science and technology across diagnostics, medicines, and digital solutions to prevent, stop and cure diseases.
- https://www.roche.com/about/businessOur unique setup is the foundation of our success. The combined strength of our Diagnostics and Pharmaceuticals divisions enables us to positively impact patients, families, communities and healthcare systems around the world. We are committed to preventing, h
- https://www.roche.com/about/business/diagnosticsWe combine science, data and insights to transform the way diseases can be prevented, diagnosed and monitored. Our medical assays, digital solutions and services help people live healthier lives.
- https://www.roche.com/about/business/pharmaceuticalsDeveloping innovative treatments across major disease areas, Roche Pharma is focused on translating excellence in science into effective medicines for patients.
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Open Graph typePassed
43/43 applicable observations passed. 1.00/1 checklist weight earned.
How to improve: Declare og:type, such as website or article.
- https://www.roche.com/website
- https://www.roche.com/aboutwebsite
- https://www.roche.com/about/businesswebsite
- https://www.roche.com/about/business/diagnosticswebsite
- https://www.roche.com/about/business/pharmaceuticalswebsite
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Open Graph URLPassed
43/43 applicable observations passed. 1.00/1 checklist weight earned.
How to improve: Set og:url to an absolute HTTP(S) URL for this content.
- https://www.roche.com/https://www.roche.com/home
- https://www.roche.com/abouthttps://www.roche.com/about
- https://www.roche.com/about/businesshttps://www.roche.com/about/business
- https://www.roche.com/about/business/diagnosticshttps://www.roche.com/about/business/diagnostics
- https://www.roche.com/about/business/pharmaceuticalshttps://www.roche.com/about/business/pharmaceuticals
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Open Graph image URLPassed
43/43 applicable observations passed. 1.00/1 checklist weight earned.
How to improve: Set og:image to an absolute HTTP(S) image URL. Homepage image availability is checked separately.
- https://www.roche.com/https://assets.roche.com/f/176343/1920x1080/0234c60f2d/home-teaser.jpg
- https://www.roche.com/abouthttps://assets.roche.com/f/176343/4000x2668/5a5b318674/06-pred-antibiotics-s2498-1.jpeg
- https://www.roche.com/about/businesshttps://assets.roche.com/f/176343/1280x853/eb20db01aa/roche_3776.png
- https://www.roche.com/about/business/diagnosticshttps://assets.roche.com/f/176343/608x355/3137bcd1be/diagnostics-teaser.jpg
- https://www.roche.com/about/business/pharmaceuticalshttps://assets.roche.com/f/176343/608x355/f2d57ffe90/pharmaceuticals-teaser.jpg
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Open Graph image descriptionNeeds work
0/43 applicable observations passed. 0.00/1 checklist weight earned.
How to improve: Describe the sharing image with og:image:alt.
- https://www.roche.com/No sharing image description
- https://www.roche.com/aboutNo sharing image description
- https://www.roche.com/about/businessNo sharing image description
- https://www.roche.com/about/business/diagnosticsNo sharing image description
- https://www.roche.com/about/business/pharmaceuticalsNo sharing image description
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Social card typePassed
43/43 applicable observations passed. 1.00/1 checklist weight earned.
How to improve: Declare twitter:card as summary or summary_large_image for a website card.
- https://www.roche.com/summary
- https://www.roche.com/aboutsummary
- https://www.roche.com/about/businesssummary
- https://www.roche.com/about/business/diagnosticssummary
- https://www.roche.com/about/business/pharmaceuticalssummary
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Homepage favicon availablePassed
1/1 applicable observations passed. 1.00/1 checklist weight earned.
How to improve: Serve a non-empty public image with an image Content-Type.
- https://www.roche.com/favicon-32x32.png?v=7f5356ff0eaba89671bed4a1828ef379HTTP 200; image/png
Homepage sharing image availableNot verified
0/1 applicable observations passed. 0.00/1 checklist weight earned.
How to improve: Check access, image size and Content-Type, then rescan.
- https://assets.roche.com/f/176343/1920x1080/0234c60f2d/home-teaser.jpgThe image could not be fetched within the network policy and 2 MB limit.
Security0 to improve
HTTPS pagePassed
43/43 applicable observations passed. 1.00/1 checklist weight earned.
How to improve: Serve the page over HTTPS with a valid certificate.
- https://www.roche.com/https://www.roche.com/
- https://www.roche.com/abouthttps://www.roche.com/about
- https://www.roche.com/about/businesshttps://www.roche.com/about/business
- https://www.roche.com/about/business/diagnosticshttps://www.roche.com/about/business/diagnostics
- https://www.roche.com/about/business/pharmaceuticalshttps://www.roche.com/about/business/pharmaceuticals
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
No insecure embedded resourcesPassed
43/43 applicable observations passed. 1.00/1 checklist weight earned.
How to improve: Use HTTPS for embedded script, image, stylesheet, frame, audio and video URLs.
- https://www.roche.com/0 HTTP embedded resource URL(s)
- https://www.roche.com/about0 HTTP embedded resource URL(s)
- https://www.roche.com/about/business0 HTTP embedded resource URL(s)
- https://www.roche.com/about/business/diagnostics0 HTTP embedded resource URL(s)
- https://www.roche.com/about/business/pharmaceuticals0 HTTP embedded resource URL(s)
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
HSTS declaredPassed
1/1 applicable observations passed. 1.00/1 checklist weight earned.
How to improve: Send Strict-Transport-Security on HTTPS responses with max-age of at least 15552000 seconds (180 days); OWASP recommends one year and includeSubDomains. Reference: OWASP HTTP Strict Transport Security cheat sheet, MDN.
- https://www.roche.com/Strict-Transport-Security: max-age=31536000
Content Security Policy declaredPassed
1/1 applicable observations passed. 1.00/1 checklist weight earned.
How to improve: Send a Content-Security-Policy header (or a <meta http-equiv="Content-Security-Policy"> on the page) that restricts script and resource sources. This check verifies presence, not policy strength. Reference: OWASP Content Security Policy cheat sheet, MDN.
- https://www.roche.com/Content-Security-Policy: frame-ancestors 'self' https://app.storyblok.com
AI access0 to improve
Content in initial HTMLPassed
43/43 applicable observations passed. 1.00/1 checklist weight earned.
How to improve: Render meaningful main content on the server so readers can access it without executing JavaScript.
- https://www.roche.com/3372 characters of crawler-visible content (minimum 100)
- https://www.roche.com/about3801 characters of crawler-visible content (minimum 100)
- https://www.roche.com/about/business1791 characters of crawler-visible content (minimum 100)
- https://www.roche.com/about/business/diagnostics3914 characters of crawler-visible content (minimum 100)
- https://www.roche.com/about/business/pharmaceuticals4721 characters of crawler-visible content (minimum 100)
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Performance1 to improve
HTML transfer budgetNeeds work
40/43 applicable observations passed. 0.93/1 checklist weight earned.
How to improve: Keep the uncompressed HTML at or below 500 KB. Remove duplicated inline payloads and unnecessary markup.
- https://www.roche.com/about/sustainability/esg-index503,185 bytes of HTML; budget 500,000
- https://www.roche.com/investors/bonds526,249 bytes of HTML; budget 500,000
- https://www.roche.com/investors/downloads515,357 bytes of HTML; budget 500,000
- https://www.roche.com/434,275 bytes of HTML; budget 500,000
- https://www.roche.com/about428,531 bytes of HTML; budget 500,000
Showing up to five examples, with failed observations first. Full per-page observations are listed below and available in the report API.
Repeated homepage HTTP responsePassed
1/1 applicable observations passed. Informational; excluded from points.
How to improve: Improve server response and CDN caching. Median of three requests; diagnostic only, never a ranking tiebreak.
- https://www.roche.com/3/3 successful measurements to response headers. Includes DNS and TLS; excludes rendering.
Browser loading and Core Web VitalsNot verified
0/1 applicable observations passed. Informational; excluded from points.
How to improve: Measure LCP, INP and CLS with browser and field tools.
- https://www.roche.com/Requires a browser or human assessment; excluded from points.
Checklist quality-v4. Competitive weights: SEO 25%, Accessibility 25%, Structure 25%, Sharing 10%, Security 15%. AI access and Performance are diagnostic only. This expanded report may include pages outside the competitive sample. Unverified scored checks earn no points; not-applicable and manual checks are excluded. Full methodology and references.
HTTP response timings
HTTP response time measured by our crawler; not browser loading speed.
- https://www.roche.com/innovation/ethical-standards/animal-research3,284 ms
- https://www.roche.com/about/sustainability/approach3,105 ms
- https://www.roche.com/about/governance2,985 ms
- https://www.roche.com/about/governance/code-of-conduct2,914 ms
- https://www.roche.com/about/governance/annual-general-meetings2,771 ms
Pages inspected (43)
All 43 pages from this scan.
| Page | Status | Title | H1 | ms |
|---|---|---|---|---|
| https://www.roche.com/ | 200 | Roche - Doing now what patients need nextPage checklist evidence
| 0 | 1,841 |
| https://www.roche.com/about | 200 | Roche | About RochePage checklist evidence
| 1 | 875 |
| https://www.roche.com/about/business | 200 | Roche | Our businessPage checklist evidence
| 1 | 877 |
| https://www.roche.com/about/business/diagnostics | 200 | Roche | Roche DiagnosticsPage checklist evidence
| 1 | 2,401 |
| https://www.roche.com/about/business/pharmaceuticals | 200 | Roche | Roche PharmaceuticalsPage checklist evidence
| 1 | 2,210 |
| https://www.roche.com/about/governance | 200 | Roche | GovernancePage checklist evidence
| 1 | 2,985 |
| https://www.roche.com/about/governance/annual-general-meetings | 200 | Roche | Annual General MeetingPage checklist evidence
| 1 | 2,771 |
| https://www.roche.com/about/governance/board-of-directors | 200 | Roche | Board of DirectorsPage checklist evidence
| 1 | 907 |
| https://www.roche.com/about/governance/code-of-conduct | 200 | Roche | Code of conductPage checklist evidence
| 1 | 2,914 |
| https://www.roche.com/about/governance/committees | 200 | Roche | Board CommitteesPage checklist evidence
| 1 | 2,216 |
| https://www.roche.com/about/governance/executive-committee | 200 | Roche | Executive committeePage checklist evidence
| 1 | 893 |
| https://www.roche.com/about/governance/risk-management | 200 | Roche | Risk managementPage checklist evidence
| 1 | 884 |
| https://www.roche.com/about/history | 200 | Roche | Our historyPage checklist evidence
| 1 | 2,426 |
| https://www.roche.com/about/leadership | 200 | Roche | Meet our leadership teamPage checklist evidence
| 1 | 904 |
| https://www.roche.com/about/roche-global-citizenship | 200 | Roche | Roche Global CitizenshipPage checklist evidence
| 1 | 867 |
| https://www.roche.com/about/strategy | 200 | Roche | Our strategyPage checklist evidence
| 1 | 1,853 |
| https://www.roche.com/about/sustainability | 200 | Roche | SustainabilityPage checklist evidence
| 1 | 1,031 |
| https://www.roche.com/about/sustainability/approach | 200 | Roche | Our approach to sustainability governancePage checklist evidence
| 1 | 3,105 |
| https://www.roche.com/about/sustainability/esg-index | 200 | Roche | ESG IndexPage checklist evidence
| 1 | 2,101 |
| https://www.roche.com/about/sustainability/goals-performance | 200 | Roche | Our environmental goals and impactPage checklist evidence
| 1 | 843 |
| https://www.roche.com/about/ | 200 | Roche | About RochePage checklist evidence
| 1 | 1,045 |
| https://www.roche.com/about/inclusion-belonging | 200 | Roche | Inclusion and Belonging at RochePage checklist evidence
| 1 | 2,545 |
| https://www.roche.com/accessibility-statement | 200 | Roche | Accessibility statementPage checklist evidence
| 1 | 2,153 |
| https://www.roche.com/contact | 200 | Roche | Contact usPage checklist evidence
| 1 | 850 |
| https://www.roche.com/innovation | 200 | Roche | InnovationPage checklist evidence
| 1 | 907 |
| https://www.roche.com/innovation/ | 200 | Roche | InnovationPage checklist evidence
| 1 | 2,392 |
| https://www.roche.com/innovation/clinical-trials | 200 | Roche | Clinical TrialsPage checklist evidence
| 1 | 953 |
| https://www.roche.com/innovation/ethical-standards | 200 | Roche | Ethical standardsPage checklist evidence
| 1 | 1,417 |
| https://www.roche.com/innovation/ethical-standards/advisory | 200 | Roche | Resolving ethical conflicts: Scientific Ethics Advisory GroupPage checklist evidence
| 1 | 2,144 |
| https://www.roche.com/innovation/ethical-standards/animal-research | 200 | Roche | Animal ResearchPage checklist evidence
| 1 | 3,284 |
| https://www.roche.com/innovation/ethical-standards/genetics | 200 | Roche | Ethical standards in genetic researchPage checklist evidence
| 1 | 2,368 |
| https://www.roche.com/innovation/partnering | 200 | Roche | PartneringPage checklist evidence
| 1 | 909 |
| https://www.roche.com/innovation/partnering/areas-of-interest | 200 | Roche | Partnering areas of interestPage checklist evidence
| 1 | 888 |
| https://www.roche.com/innovation/partnering/diagnostics | 200 | Roche | Partnering with DiagnosticsPage checklist evidence
| 1 | 928 |
| https://www.roche.com/innovation/partnering/pharma | 200 | Roche | Partnering with PharmaPage checklist evidence
| 1 | 935 |
| https://www.roche.com/innovation/process | 200 | Roche | Innovation processPage checklist evidence
| 1 | 899 |
| https://www.roche.com/innovation/structure | 200 | Roche | Our teams and structurePage checklist evidence
| 1 | 947 |
| https://www.roche.com/innovation/structure/rnd-locations | 200 | Roche | R&D locationsPage checklist evidence
| 1 | 918 |
| https://www.roche.com/investors | 200 | Roche | InvestorsPage checklist evidence
| 1 | 1,438 |
| https://www.roche.com/investors/ | 200 | Roche | InvestorsPage checklist evidence
| 1 | 1,260 |
| https://www.roche.com/investors/annualreport25 | 200 | Roche | Roche’s Annual Report 2025Page checklist evidence
| 1 | 891 |
| https://www.roche.com/investors/bonds | 200 | Roche | Share and Bond informationPage checklist evidence
| 1 | 908 |
| https://www.roche.com/investors/downloads | 200 | Roche | Investor downloadsPage checklist evidence
| 1 | 901 |
Optional AI signals
Informational signals; these do not certify search visibility or unlock S-Tier.
- llms.txtGuide for AI agents
- Structured dataJSON-LD on the homepage
- Semantic HTMLMain and navigation landmarks
Browser measurements · supplementary
Mobile page report
roche.com
https://roche.com/
Measured · 10/27/2026, 11:47:33 PM UTC
Redirected to: https://www.roche.com/
- Speed
- 46
- Accessibility
- 100
- SEO basics
- 100
- Main content (LCP)
- 14.1 s
- Layout shifts (CLS)
- 0.031
- Blocking time (TBT)
- 420 ms
Measurement notes (1)
- The page may not be loading as expected because your test URL (https://roche.com/) was redirected to https://www.roche.com/. Try testing the second URL directly.
Your next improvements
Measured findings to investigate, ordered by audit score.
1. Network dependency tree
[Avoid chaining critical requests](https://developer.chrome.com/docs/performance/insights/network-dependency-tree) by reducing the length of chains, reducing the download size of resources, or deferring the download of unnecessary resources to improve page load.
2. Largest Contentful Paint
Largest Contentful Paint marks the time at which the largest text or image is painted. [Learn more about the Largest Contentful Paint metric](https://developer.chrome.com/docs/lighthouse/performance/lighthouse-largest-contentful-paint/)
3. Forced reflow
A forced reflow occurs when JavaScript queries geometric properties (such as `offsetWidth`) after styles have been invalidated by a change to the DOM state. This can result in poor performance. Learn more about [forced reflows](https://developer.chrome.com/docs/performance/insights/forced-reflow) and possible mitigations.
4. LCP breakdown
Each [subpart has specific improvement strategies](https://developer.chrome.com/docs/performance/insights/lcp-breakdown). Ideally, most of the LCP time should be spent on loading the resources, not within delays.
5. LCP request discovery
[Optimize LCP](https://developer.chrome.com/docs/performance/insights/lcp-discovery) by making the LCP image discoverable from the HTML immediately, and avoiding lazy-loading
6. First Contentful Paint
First Contentful Paint marks the time at which the first text or image is painted. [Learn more about the First Contentful Paint metric](https://developer.chrome.com/docs/lighthouse/performance/first-contentful-paint/).
7. Time to Interactive
Time to Interactive is the amount of time it takes for the page to become fully interactive. [Learn more about the Time to Interactive metric](https://developer.chrome.com/docs/lighthouse/performance/interactive/).
8. Speed Index
Speed Index shows how quickly the contents of a page are visibly populated. [Learn more about the Speed Index metric](https://developer.chrome.com/docs/lighthouse/performance/speed-index/).
Fix with your coding assistant
Copy a ready-to-use prompt with the issues and affected URLs.
Battle scoring rules
The arena winner follows the verified ranking: internal link health first, then the published two-decimal quality score. Both sites need two agreeing standard observations. Browser performance, accessibility and SEO are complementary diagnostics and do not move the ranking or decide its winner. Page-only battles compare compatible rounds; performance differences up to five points draw, and equal round wins remain a tie. Missing measurements never count as zero. Browser audits do not certify accessibility. Saved results keep their measured evidence; start a rematch for a newer comparison.